PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer.
Liedtke C, Cardone L, Tordai A, Yan K, Gomez HL, Figureoa LJ, Hubbard RE, Valero V, Souchon EA, Symmans WF, Hortobagyi GN, Bardelli A, Pusztai L.
Liedtke C, et al.
Breast Cancer Res. 2008;10(2):R27. doi: 10.1186/bcr1984. Epub 2008 Mar 27.
Breast Cancer Res. 2008.
PMID: 18371219
Free PMC article.